Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)

April 2018 | 82 pages | ID: GACC87B70A2EN
Koncept Analytics

Abstracts

‘Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which includes the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, family history and personal history are linked to the growth of breast cancer.

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, increasing adoption of minimally invasive procedures and rising awareness programs and research grants. However, growth of the market can be hindered by several factors including financial burden of breast cancer, drug development challenges in developing countries, long term side effects of drugs.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Contents

1. INTRODUCTION

1.1 Breast Cancer
1.2 Types
1.3 Stages
1.4 Risk Factors
1.4 Symptoms & Diagnosis
1.5 Treatment

2. GLOBAL BREAST CANCER MARKET

2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

3. REGIONAL BREAST CANCER MARKET ANALYSIS

3.1 The U.S.
  3.1.1 The U.S. Breast Cancer Market by Value
  3.1.2 The U.S. Breast Cancer Market Forecast by Value
  3.1.3 The U.S. Breast Cancer Market by Addressable Population
  3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
  3.1.5 The U.S. Breast Cancer Population by Age
  3.1.6 The US HER2+ Node Positive Breast Cancer Patients Volume
  3.1.7 The US HER2+ Node Negative Breast Cancer Patients Volume
  3.1.8 The US HER2+ Node Negative (High Risk) Breast Cancer Patients Volume
3.2 Europe
  3.2.1 EU5 Breast Cancer Market by Value
  3.2.2 EU5 Breast Cancer Market Forecast by Value
  3.2.3 Europe HER2+ Node Positive Breast Cancer Patients Volume
  3.2.4 Europe HER2+ Node Negative Breast Cancer Patients Volume
  3.2.5 Europe HER2+ Node Negative (High Risk) Breast Cancer Patients Volume
3.3 APAC
  3.3.1 APAC Breast Cancer Market by Value
  3.3.2 APAC Breast Cancer Market Forecast by Value
  3.3.3 APAC Breast Cancer Market by Countries
  3.3.4 Japan’s Breast Cancer Market by Value
  3.3.5 Japan’s Breast Cancer Market Forecast by Value
  3.3.6 China’s Breast Cancer Market by Value
  3.3.7 China’s Breast Cancer Market Forecast by Value
  3.3.8 Australia’s Breast Cancer Market by Value
  3.3.9 Australia’s Breast Cancer Market Forecast by Value

4. MARKET DYNAMICS

4.1 Growth Drivers
  4.1.1 Rising Consumption of Tobacco and Alcohol
  4.1.2 Increasing Global Diabetic Population
  4.1.3 Accelerating Obese Population
  4.1.4 Increasing Healthcare Expenditure Per Capita
  4.1.5 Rising Female Population Aged 65 Years & Above
4.2 Key Trends & Developments
  4.2.1 PARP Inhibitors under Development
  4.2.32Rising Adoption of Minimally Invasive Procedures
  4.2.3 Increasing Awareness Programs and Research Grants
4.3 Challenges
  4.3.1 Financial Burden of Breast Cancer
  4.3.2 Drug Development Challenges in Developing Countries
  4.3.3 Long Term Side Effects

5. COMPETITION

5.1 Global Market
  5.1.1 Revenue Comparison by Company
  5.1.2 R&D Expenditure Comparison by Company
  5.1.3 Market Cap Comparison by Company

6. COMPANY PROFILES

6.1 Johnson & Johnson
  6.1.1 Business Overview
  6.1.2 Financial Overview
  6.1.3 Business Strategies
6.2 AstraZeneca
  6.2.1 Business Overview
  6.2.2 Financial Overview
  6.2.3 Business Strategies
6.3 AbbVie Inc.
  6.3.1 Business Overview
  6.3.2 Financial Overview
  6.3.3 Business Strategies
6.4 Roche
  6.4.1 Business Overview
  6.4.2 Financial Overview
  6.4.3 Business Strategies

List Of Charts

LIST OF CHARTS

Breast Cancer by Types
Stage Occurrence of Breast Cancer in Patients
Global Breast Cancer Market by Value (2013-2017)
Global Breast Cancer Market Forecast by Value (2018-2022)
Global Breast Cancer Market by Region (2017)
Global Breast Cancer Drug Development by Stages (2017)
The U.S. Breast Cancer Market by Value (2013-2017)
The U.S. Breast Cancer Market Forecast by Value (2018-2022)
The U.S. Breast Cancer Market by Addressable Population (2013-2017)
The U.S. Breast Cancer Market Forecast by Addressable Population (2018-2022)
The U.S. Breast Cancer Population by Age & Type (2017)
The U.S. HER2+ Node Positive Breast Cancer Patients Volume (2017-2022)
The U.S. HER2+ Node Negative Breast Cancer Patients Volume (2017-2022)
The U.S. HER2+ Node Negative (High Risk) Breast Cancer Patients Volume (2017-2022)
EU5 Breast Cancer Market by Value (2013-2017)
EU5 Breast Cancer Market Forecast by Value (2018-2022)
Europe HER2+ Node Positive Breast Cancer Patients Volume (2017-2022)
Europe HER2+ Node Negative Breast Cancer Patients Volume (2017-2022)
Europe HER+ Node Negative (High Risk) Breast Cancer Patients Volume (2017-2022)
APAC Breast Cancer Market by Value (2013-2017)
APAC Breast Cancer Market Forecast by Value (2018-2022)
APAC Breast Cancer Market by Countries (2017)
Japan’s Breast Cancer Market by Value (2013-2017)
Japan’s Breast Cancer Market Forecast by Value (2018-2022)
China’s Breast Cancer Market by Value (2013-2017)
China’s Breast Cancer Market Forecast by Value (2018-2022)
Australia's Breast Cancer Market by Value (2013-2017)
Australia's Breast Cancer Forecast Market by Value (2018-2022)
Global Cigarette Consumption (1990-2017)
Global Diabetic Population (2013-2017)
Global Obese Population (2013-2017)
Global Healthcare Expenditure Per Capita (2013-2017)
Global Female Population Aged 65 Years and Above (2013-2017)
Revenue Comparison by Company (2017)
R&D Expenditure Comparison by Company (2017)
Market Cap Comparison by Company (2017)
Johnson & Johnson Sales by Segments (2017)
Johnson & Johnson Sales and Net Earnings (2013-2017)
AstraZeneca Product Revenue by Region (2017)
AstraZeneca Revenue and Net Profit (2013-2017)
AstraZeneca Development Pipeline Overview (2017)
AbbVie Revenue by Product Segments (2017)
AbbVie Revenue and Net Earnings (2013-2017)
Roche Sales by Segments (2017)
Roche Sales and Net Income (2013-2017)

List Of Tables

LIST OF TABLES

Stages of Breast Cancer
Key PARP Inhibitors Under Development (2017)
Johnson & Johnson Product Pipeline (2017)
AbbVie Inc. Agreements (2017/2018)
AbbVie Inc. Major Product Approvals (2017/2018)
Roche Agreements (2017/2018)
Roche Product Approvals & Launches (2017/2018)